Adicet Bio (LTS:0HX7) Other Long-Term Liabilities : $0.12 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Other Long-Term Liabilities?

Adicet Bio's other long-term liabilities for the quarter that ended in Mar. 2025 was $0.12 Mil.

Adicet Bio's quarterly other long-term liabilities stayed the same from Sep. 2024 ($0.12 Mil) to Dec. 2024 ($0.12 Mil) and stayed the same from Dec. 2024 ($0.12 Mil) to Mar. 2025 ($0.12 Mil).

Adicet Bio's annual other long-term liabilities increased from Dec. 2022 ($0.11 Mil) to Dec. 2023 ($0.13 Mil) but then declined from Dec. 2023 ($0.13 Mil) to Dec. 2024 ($0.12 Mil).

Adicet Bio Other Long-Term Liabilities Historical Data

The historical data trend for Adicet Bio's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicet Bio Other Long-Term Liabilities Chart

Adicet Bio Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long-Term Liabilities

Get a 7-Day Free Trial

0.98

0.11

0.13

0.12

Adicet Bio Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Long-Term Liabilities	Get a 7-Day Free Trial															0.12	0.12	0.12	0.12	0.12

Adicet Bio Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Adicet Bio Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Adicet Bio's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Adicet Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (LTS:0HX7) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

ACET:USA 1IJA:Germany 1IJA:Germany

Address

131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116

Website

https://www.adicetbio.com

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Adicet Bio Headlines

No Headlines